SecBot SecBot
PRESS-RELEASE ·Filed May 5, 2026

DRTS

Alpha Tau Medical Ltd.
BULLISH
Impact 5/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Monitor the AHNS presentation on July 21, 2026, for top-line efficacy and safety data. Positive results could drive near-term interest in DRTS, but regulatory and commercialization timelines remain distant.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$7.39
T+0 close · May 5, 2026 · via day close
Latest settled
+60.89%
T+60 · $11.89
Vs SPY
+58.15%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $7.39entry
  2. T+1 · 7mo ago +2.71%α +1.32% · $7.59
  3. T+5 · 6mo ago +39.92%α +37.93% · $10.34
  4. T+20 · 6mo ago +20.84%α +15.88% · $8.93
  5. T+60 · 4mo ago +60.89%α +58.15% · $11.89
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau Medical announced that an abstract on Alpha DaRT in combination with pembrolizumab for elderly patients with head and neck cancer has been accepted for a podium presentation at the AHNS International Conference (July 18-22, 2026). This marks a strategic milestone for the company's combination therapy program, building on prior monotherapy data.

Key Facts

  • Abstract accepted for podium presentation at AHNS International Conference on Head and Neck Cancer (July 21, 2026)
  • Study evaluates Alpha DaRT + pembrolizumab in elderly patients with locally advanced/metastatic HNSCC
  • Complete top-line data to be presented; builds on prior monotherapy safety data
  • Elderly HNSCC patients have limited treatment options, representing a significant unmet need

Financial Impact

No financial data provided; potential upside if combination data is positive, but no revenue impact expected near-term

Risk Factors

  • Clinical trial data may not meet expectations
  • Competition from other intratumoral therapies and immunotherapies
  • Regulatory approval and reimbursement uncertainties

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
80% bullish (10 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3287848

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026